S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Financial Stocks Steady as NatWest and Coinbase Pivot Strategies

Global financial shares leveled off this week after a period of heightened market volatility, as major players like NatWest and Coinbase Technology adjusted their outlooks to navigate shifting interest rates and fluctuating asset values.

Financial Stocks Steady as NatWest and Coinbase Pivot Strategies

Shares of banks and other financial institutions remained largely unchanged following a turbulent week for global markets. Investors are currently weighing the impact of macroeconomic uncertainty against specific corporate growth strategies, resulting in a neutral performance across the broader sector.

Strategic Shifts and Digital Recovery

British lender NatWest projected continued income growth and higher profitability for the current year and beyond. According to the company, the bank is prioritizing an expansion into wealth management to attract new clients and diversify its earnings. This strategic pivot aims to provide a buffer against the revenue pressure expected from falling interest rates in the U.K. market.

In the digital asset sector, Coinbase Technology shares surged as a rebound in bitcoin prices helped investors look past a lackluster fourth-quarter earnings report. While the recent rally offered temporary relief, the exchange's stock price remains approximately 30% lower for the year to date, mirroring the broader volatility seen across the cryptocurrency landscape.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!